Together with its subsidiaries, the company engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products.
If you look at the long term chart, you will see that the stock channels between approximately $7 and $14, and has done so for a couple years. The stock is now at the bottom of the channel (last trade was $7.09), just in time for flu season.
Here is what you need to know:
- P/E Ratio (TTM) of just 10.41, versus the industry's average of 24.1
- Has an incredibly consistent record of increasing sales at 50% year-over-year and earnings 30-40% year-over-year
- Positioning itself for even further growth through the recent signing of a letter of intent to acquire a leading pharmaceutical business in China
- $144.4 Million in cash and only $10.78 Million in debt
- 21% of the shares are held by insiders; institutions hold 58.90%
- 4 analysts rate it a "Strong Buy", 1 calls it a "Buy"
$7.05 (09/29/08)
